Shanghai Shyndec Pharmaceutical (600420.SH): The efficacy of enalapril maleate tablets was evaluated through consistency assessment.
Guoyao Xian Dai (600420.SH) announcement, the company has received the approval and issuance of the "Supplementary Drug..." from the State Food and Drug Administration.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that the company has received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration, approving the consistency evaluation of the generic quality and efficacy of 5mg perindopril maleate tablets. Perindopril maleate is an angiotensin-converting enzyme inhibitor mainly used to treat primary hypertension, renal vascular hypertension, and symptomatic heart failure.
Related Articles
According to SICC Co., Ltd. (02631), 7.1618 million shares were issued by exercising all excess rights issues.
On September 17th, LINKLOGIS-W (09959) spent 7.4586 million Hong Kong dollars to repurchase 2.3 million shares.
BRII-B (02137) was allocated 159,900 restricted share units.
According to SICC Co., Ltd. (02631), 7.1618 million shares were issued by exercising all excess rights issues.
On September 17th, LINKLOGIS-W (09959) spent 7.4586 million Hong Kong dollars to repurchase 2.3 million shares.
BRII-B (02137) was allocated 159,900 restricted share units.
